

Proventa International's 11th Annual

# MEDICINAL CHEMISTRY

STRATEGY MEETING WEST COAST USA 2024

**⊞ Wednesday, 22nd May 2024 ② Hard Rock Hotel San Diego** 

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

### Featuring Industry Leaders and Decision Makers:



Prasun Mishra Agility Pharmaceuticals, **Agility** 

**Pharmaceuticals** 



Andrea Small-Howard **GB** Sciences



Arun **Thottumkara Director Chemistry** Odyssey Therapeutics



Brock Shireman Vice President, Head of Chemistry Rapport Therapeutics



Bryce Allen & CEO Differentiated **Therapeutics** 



Yoshi Satoh Vice President of Chemistry Rev Therapeyutics



Yuhua Ji Grace Science



20 ROUNDTABLE



5 TRACKS



KEYNOTE **PRESENTATIONS** 



PANEL DISCUSSION



LOCATION



**What Makes Our Strategy** Meetings So Unique?

#### Proud to Partners with:

























# Proventa International's Strategy Meetings are a completely unique experience.

### MEDICINAL CHEMISTRY

STRATEGY MEETING WEST COAST USA 2024


We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.



To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.



By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.





#### **COUNDTABLE DISCUSSIONS**

These interactive and informal discussion ups are the hallmark of the meeting. brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.



The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings



#### STRATEGIC NETWORKING


Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that

### Seniority of Attendees

- **Director Level**
- President / VP
- **Department Head**
- Other
- Team Lead
- C-Level
- Scientist
- Academia
  - Manager

**BOOK NOW!** 

**Biology Specialist** 



Medicinal Chemistry ✓ R&D

- ✓ Drug Discovery
- Computational Chemistry
- Cheminformatics
- ✓ CMC
- External Innovation
- Pre-Clinical
- Artificial Intelligence

# Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/
- Sovereign Wealth Fund
- Angel





**Medicinal Chemistry** 







# **Facilitator Faculty**

# **MEDICINAL CHEMISTRY**

**STRATEGY MEETING WEST COAST USA 2024** 

Wednesday, 22nd May 2024 & Hard Rock Hotel San Diego



**Chris Stumpf** Director, Drug Discovery Informatics Solutions Revvity Signals



Prasun Mishra CEO, Founder and CEO, Agility Pharmaceuticals, Founding President, American Medicine (AAPM) **Agility Pharmaceuticals** 



**BOOK NOW!** 

Andrea Small-Howard **GB** Sciences



Arun Thottumkara Director Chemistry **Odyssey Therapeutics** 



**Brock Shireman** Head of Chemistry Rapport Therapeutics



Bryce Allen Co-founder & CEO Differentiated Therapeutics



**Vuong Trieu** Oncotelic



Sanjeev Thohan Scientific Advisory Board Member Cogentis Therapeutics/ **Phoenix Molecular** Designs



Yuhua Ji VP of Drug Discovery Grace Science



Yoshi Satoh Vice President of **Rev Therapeyutics** 









@proventaintl

# 2024 Sponsors

### **MEDICINAL CHEMISTRY**

STRATEGY MEETING EAST COAST USA 2024

₩ Wednesday, 22nd May 2024 Hard Rock Hotel San Diego

#### **CO-HOST SPONSOR**



**Jubilant Biosys Ltd.** Is a part of Jubilant Pharmova group of companies with R&D centres in India and business offices in Asia, North America, UK and EU. Jubilant Biosys provides comprehensive drug discovery, contract research, development and manufacturing services. Our drug discovery services range from target validation to candidate selection, and CDMO services offer manufacturing support from clinical to commercial stage. We offer stand-alone services across entire continuum of drug discovery, including computational, medicinal, synthetic & analytical chemistry, structural biology, in-vivo & in-vitro biology, DMPK/ADME & toxicology. Our scale up & manufacturing facility in India with 900+ MTs reactor capacity is accredited by U.S. FDA, PMDA, and EMA. Tech. transfer from lab scale synthesis to manufacturing is supported by our on-site R&D, QC, QA, EHS, PM and engineering experts. This is indeed the reason why Jubilant Biosys is a partner of choice for pharma & biotech companies across the globe.

#### **PARTNERING SPONSORS**





#### **KEY OPINION LEADERS**







# **1** 8

### **Global Sponsorship Opportunities**

Proventa's end-to-end consulting division gather real-time business intelligence on the industry's **needs**, **challenges**, **budgets** and **investment areas**. We combine this information with your specific needs to enhance your business development strategy. With the wealth of intel we provide, Proventa guarantees tangible results for your business within twelve months of the event.

For Sponsorship Opportunites please contact:

SPONSORSHIP TEAM: <a href="mailto:info@proventainternational.com">info@proventainternational.com</a> | +44 (0)208 124 6417





#### **MEDICINAL CHEMISTRY**

**STRATEGY MEETING WEST COAST USA 2024** 

PDT UNDRUGGABLES / INNOVATIVE & OPTIMIZATION EMERGING MODALITIES	NTEGRATED DRUG DISCOVERY
PREAVEACT O RECICEDATION	RIEGRATED DROG DISCOVERT
08:00 - 08:30 BREAKFAST & REGISTRATION	
OPENING KEYNOTE PRESENTATION:  A Deep Dive into the Synergies of Artificial Intelligence and Drug Discovery for Precision Medicine  PRESENTER: Andrea Small-Howard, President, GB Sciences	
Past 10 years and Projecting the Future 10 O9:00 - 10:00 PHARMA/ BIOTECH  Past 10 years and Projecting the Future 10 Chemical Biology Approaches  Precision and Efficiency in Lead Optimization and Hit Identification (Topic TBC) Andrea Small-Howard, President, GB Science  Precision and Efficiency in Lead Optimization and Hit Identification (Topic TBC)  Wuong Trieu, CEO, Oncotelic  Arun Thottumkara, Director Chemistry, Odyssey Therapeutics	eraging ADME-PKPD relationships and hanistic toxicology while building bridges ween translational sciences is crucial for ctive drug development, spanning from ecules to medicines  Sanjeev Thohan, Scientific Advisory Board Member, Cogentis Therapeutics/Phoenix Molecular Designs
10:00 - 10:05 REFRESHMENT BREAK	
10:05 - 10:25 NETWORKING / 1-1 MEETINGS	
10:25 - 10:45 NETWORKING / 1-1 MEETINGS 10:45 - 11:05 NETWORKING / 1-1 MEETINGS	
Implementing De Novo for Generative Accelerating innovation in drug modalities Models to Molecular Design on Drug Accelerating innovation in drug modalities of Molecular Dynamics (MD) The Best Methods for Synthesizing Accelerating Molecular Dynamics (MD) Simulations for Fragment-Based Drug Quantities Ranging From Milligrams To	elerating innovation in drug modalities earch through CRO, CDMO, CMO, and demia partnerships
11:10 - 12:10  Chris Stumpf, Director, Drug Discovery Informatics Solutions, Revvity Signals  SOLUTION	
sponsor revvity signals  Sponsor sponsor  revvity signals	SPONSOR
12:15 - 13:15 Discovery (Topic TBC) in Undruggable Leads (Topic TBC) What to Do Early in Lead Generation and Lead Optimization  PHARMA/  POTECL  PHARMA/  PROTECL  PHARMA/  PHARMA/  PROTECL  PHARMA/  PH	as About Automating Decision Making os To Accelerate Integrated Discovery Yoshi Satoh, Vice President of Chemistry, Rev Therapeutics
13:15 - 14:00 NETWORKING LUNCH	
14:00 - 14:20 NETWORKING / 1-1 MEETINGS	
14:20 - 14:40 NETWORKING / 1-1 MEETINGS	
14:40 - 15:10 AFTERNOON KEYNOTE PRESENTATION	
Al and Generative Modeling for Molecular Cheminformatics for Chemical Synthesis using Integrated Drug Discovery in lead thinking Approaches in Design and Trium	loring Translational Challenges and mphs in Integrated Drug Discovery for I-World Clinical Impact
16:10 - 16:30 AFTERNOON REFRESHMENT BREAK	
PANEL DISCUSSION: Bridging Science and Investment: A Dialogue on Drug Discovery, Venture Strategies, Biotech Progress, and the Revolutionary Landscape of Pharmaceu  16:30 - 17:00 CHAIRPERSON: Prasun Mishra, CEO, Founder and CEO, Agility Pharmaceuticals, Founding President, American Association for Precision Medicine (AAPM), Agility Pharmaceuticals PANELIST: Sanjeev Thohan, Scientific Advisory Board Member, Cogentis Therapeutics/Phoenix Molecular Designs	
17:00 - 18:00 DRINKS & CANAPES RECEPTION	

# **Event Day** | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.





**S** 08:30 - 09:00 PT

**OPENING KEYNOTE PRESENTATION** 

A Deep Dive into the Synergies of Artificial Intelligence and Drug Discovery for Precision Medicine





Andrea Small-Howard
President and CSO
GB Sciences

#### ABOUT THE SPEAKER

Dr. Andrea Small-Howard has 25 years of scientific research and executive experience in the biopharma industry supervising research & development, manufacturing, and quality control in global divisions. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals, and orchestrated commercial licensing deals. As President, Chief Science Officer, and Board Member at Gb Sciences, Inc., she brings passion for advancing clinical research on phytochemical compounds and strategic vision for creating a novel Al-enabled drug discovery engine and biopharmaceutical drug development program for disease-specific phytomedicines.



14:40 - 15:10 PDT

AFTERNOON KEYNOTE PRESENTATION

#### **Topic TBC**



Speaker TBC

ABOUT THE SPEAKER Speaker TBC



L 16:30 - 17:00 PDT

**PANEL DISCUSSION** 

Bridging Science and Investment: A Dialogue on Drug Discovery, Venture Strategies, Biotech Progress, and the Revolutionary Landscape of Pharmaceuticals





CHAIRPERSON

Prasun Mishra
Founding Director, Chairman of the Board
Agility Pharmaceuticals



PANE

Sanjeev Thohan Scientific Advisory Board Member Cogentis Therapeutics/ Phoenix Molecular Designs

#### ABOUT THE SPEAKER

Dr. Prasun Mishra is a leading life science, technology, and healthcare thought leader and an Impact Investor. He is a scientist with numerous publications/patents to his credit. He has contributed to developing several drugs and combinations in trials and approved and has over 40 prestigious awards and over 35 keynote talks & invited lectureships. During his distinguished career, he served the pharma giant Genentech, Roche, Rutgers University and NCI, NIH, DHHS, U.S. Government. He is a Founding Partner of GSIF: Global Sustainability Impact Fund LLC. He also serves on the executive team of the Global Fund for Sustainable Development (GFSD): The United Nations SDGs Implementation Program.









# **Event Day**

AI/ML

Large quantities of biological and medical data brought by increased digitalization in the industry go hand in hand with next-level machine cognition to aid efforts involving drug discovery & development, synthesis, drug repurposing, modeling & simulation, predicting protein attachment, computer-Aided drug design (CADD), and beyond. This track explores the verifiable use of advanced technologies to analyze data, predict structure and activity, aid in hit finding and more.

STRATEGY MEETING WEST COAST USA 2024 🞹 Wednesday, 22nd May 2024 🕺 Hard Rock Hotel San Diego

08:00 - 08:30 PT

**BREAKFAST & REGISTRATION** 

**U** 08:30 - 09:00 PT

**OPENING KEYNOTE PRESENTATION** 

O9:00 - 10:00 PT **ROUNDTABLE 1** 

The Evolution of AI: Looking Back at the Past 10



years and Projecting the Future 10



Andrea Small-Howard President and CSO

ABOUT THE SPEAKER See Page 6

10:00 - 11:05 PT

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 

11:10 - 12:10 PT

**SOLUTION FOCUS ROUNDTABLE 2** 

Implementing De Novo for Generative Models to **Molecular Design on Drug Projects** 



Speaker TBC

ABOUT THE SPEAKER Speaker TBC

**BOOK NOW!** 

12:15 - 13:15 PT

**ROUNDTABLE 3** 

Leveraging Generative Modeling to Accelerate Drug Discovery(Topic TBC)



Philip Cheung Founder and Chief Executive Officer Refactor Biosciences

ABOUT THE SPEAKER

Speaker TBC

13:15 - 14:40 PT

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 

14:40 - 15:10 PT

AFTERNOON KEYNOTE PRESENTATION

15:10 - 16:10 PT

**ROUNDTABLE 4** 

Revolutionizing Drug Discovery: Unleashing Al and Generative Modeling for Molecular Innovation.



Prasun Mishra Founding Director, Chairman of the Board **Agility Pharmaceuticals** 

**ABOUT THE SPEAKER** See Page 6

16:10 - 16:30 PT

AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT

PANEL DISCUSSION

17:00 - 18:00 PT

**DRINKS & CANAPES RECEPTION** 



### **Virtual Boardrooms**

Connecting Life Science Leaders Worldwide

The biggest names, hottest topics and largest reach. Tune into our virtual boardrooms to discover the latest insights across the life sciences industry. Listen to thought leaders share their thoughts across a range of critical areas and send in your questions to be debated.











**Event Day** 

### Chemical Biology, Targeted Protein Degradation & Undruggables / **Innovative & Emerging Modalities**

Despite the reinvigorated R&D engine and reinstated productivity, challenges and opportunities remain unanswered such as optimized druggability, pharmacokinetics and safety, enhanced bioavailability, DNA-Encoded Library, Small and Large Molecules Enhancement, Covalent Fragment Libraries, and more. This track aims to tackle these current barriers, formulate an outlook strategy and explore the emerging modality space, tackles pressing topics that interrogate and discern biological function by exploring small and large molecule modulation, undruggable targets



08:00 - 08:30 PT

BREAKFAST & REGISTRATION



**U** 08:30 - 09:00 PT

**OPENING KEYNOTE PRESENTATION** 



O9:00 - 10:00 PT

**ROUNDTABLE 1** 

Identifying "Difficult-to-Drug" Targets with



**Chemical Biology Approaches** 



**ABOUT THE SPEAKER** Speaker TBC



10:00 - 11:05 PT

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 



11:10 - 12:10 PT

**SOLUTION FOCUS ROUNDTABLE 2** 

Accelerating innovation in drug modalities research through CRO, CDMO, CMO, and academia partnerships



- Challenges for drug discovery sponsors when leveraging contract partner's expertise in drug modalities research.
- Opportunities for drug discovery organizations in establishing strategic partnerships with contract partners.
- Realistic expectations for collaboration, project management, IP protection, and data sharing in sponsor-contractor partnerships.



**BOOK NOW!** 

Director, Drug Discovery Informatics Solutions **Revvity Signals** 



#### ABOUT THE SPEAKER

Chris Stumpf is Director, Drug Discovery Informatics Solutions at Revvity Signals. Chris has over 20 years of experience in the Analytical Instrumentation and Informatics industry spanning Pharmaceuticals & Life Sciences to Chemicals & Materials. He has a Ph.D. in Analytical Chemistry and Mass Spectrometry from Purdue University.



L 12:15 - 13:15 PT

**ROUNDTABLE 3** 

**Exploring the Current Formulation Challenges in Undruggable Leads (Topic TBC)** 



Brvce Allen Co-founder & CEO **Differentiated Therapeutics** 

ABOUT THE SPEAKER Speaker TBC



**I** 13:15 - 14:40 PT

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 



14:40 - 15:10 PT

AFTERNOON KEYNOTE PRESENTATION



L 15:10 - 16:10 PT

**ROUNDTABLE 4** 

**Methods of Computation and Cheminformatics** for Chemical Synthesis and Hit Finding for Tough Targets and New Therapeutic Approaches



Speaker TBC

**ABOUT THE SPEAKER** Speaker TBC



16:10 - 16:30 PT

AFTERNOON REFRESHMENT BREAK



L 16:30 - 17:00 PT

**PANEL DISCUSSION** 

17:00 - 18:00 PT

**DRINKS & CANAPES RECEPTION** 

## WHAT MAKES OUR STRATEGY MEETINGS SO UNIQUE?













## Hit Identification / Lead Optimization

The process of discerning the properties associated with each hit compound is multi-dimensional and impossibly challenging giving rise to the process of eliminating weekly active compounds - Hit to Lead. This track will investigate the steps between target validation to lead optimization, Structure-Based Drug Design Lead, High Throughput Screening, Accelerating Hit-To-Lead Optimization and Progress of Compounds for Lead Optimization, and more.



08:00 - 08:30 PT

BREAKFAST & REGISTRATION

O8:30 - 09:00 PT

**OPENING KEYNOTE PRESENTATION** 

**L** 09:00 - 10:00 PT

**ROUNDTABLE 1** 

**Using Computational Methods to Improve Precision** and Efficiency in Lead Optimization and Hit Identification (Topic TBC)





**Vuong Trieu** Oncotelic

**ABOUT THE SPEAKER** Speaker TBC

**10:00 - 11:05 PT** 

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 

L 11:10 - 12:10 PT

**SOLUTION FOCUS ROUNDTABLE 2** 

**Utilizing Molecular Dynamics (MD) Simulations** for Fragment-Based Drug Design: What are the **Advantages and Disadvantages?** 



Speaker TBC

**ABOUT THE SPEAKER** Speaker TBC

**BOOK NOW!** 



L 12:15 - 13:15 PT

**ROUNDTABLE 3** 

Efforts for "Failing Fast and Failing Early." i.e., What to Do Early in Lead Generation and Lead **Optimization** 





Yuhua li VP of Drug Discovery Grace Science

#### ABOUT THE SPEAKER

Yuhua Ji, Ph.D. has broad experiences in drug discovery and development. She has a proven track record of building team from the ground up. She led and contributed to over ten development candidates and IND-filings. Dr. Ji has extensive expertise in medicinal chemistry, CMC and preclinical development of small molecules. She is the principal inventor of revefenacin and named as the inventor on over 100 patents and the author of over 20 publications. Currently, she is VP of drug discovery at Grace Science. Previously, Dr Ji was the head of Medicinal Chemistry at Zai Lab and IND director at Virogin Biotech. During her years at Path, She led discovery chemistry and CMC, and supported several clinical development programs. She led the discovery and early development of YUPELRITM at Theravance.

13:15 - 14:40 PT

**NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS** 

14:40 - 15:10 PT

AFTERNOON KEYNOTE PRESENTATION

L 15:10 - 16:10 PT

**ROUNDTABLE 4** 

**Exploring challenges and triumphs using Integrated** Drug Discovery in lead optimization, candidate selection and IND enabling studies.



**Brock Shireman** Vice President, Head of Chemistry Rapport Therapeutics

#### **ABOUT THE SPEAKER**

Brock Shireman has an extensive work experience in the pharmaceutical industry. Brock is currently the Vice President and Head of Chemistry at Rapport Therapeutics since February 2023. Prior to that, they worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as the Senior Scientific Director from June 2019 to March 2023. Before that, they held the positions of Scientific Director and Senior Principal Scientist at Janssen Inc. from October 2017 to June 2019 and November 2014 to October 2017, respectively. Brock'scareer at Johnson & Johnson, P.R.D. includes roles such as Principal Scientist from March 2011 to November 2014. Senior Scientist from September 2007 to March 2011. and Scientist from May 2003 to September 2007. Brock Shireman's education history begins with obtaining a Bachelor's degree in Chemistry from Illinois State University from 1989 to 1993. Brock then pursued a Master's degree in Chemistry at the same institution from 1993 to 1996. Following that, Shireman attended the University of Notre Dame from 1996 to 2001, where they earned their Doctor of Philosophy degree in Organic Chemistry. Lastly, they attended Stanford University from 2001 to 2003 for a Postdoctoral fellowship in Chemistry.

L 16:10 - 16:30 PT

AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT

PANEL DISCUSSION See Page 6

17:00 - 18:00 PT

**DRINKS & CANAPES RECEPTION** 









# **Event Day Design & Synthesis** Tagline

MEDICINAL CHEMIS STRATEGY MEETING WEST COAST USA 2024 🚃 Wednesday, 22nd May 2024 🕺 Hard Rock Hotel San Diego

**08:00 - 08:30 PT** 

**BREAKFAST & REGISTRATION** 

**L** 08:30 - 09:00 PT

**OPENING KEYNOTE PRESENTATION** 

**9:00 - 10:00 PT** 

**ROUNDTABLE 1** 

**Designing the Next Generation of Drugs: Harnessing Physicochemical Properties, Streamlining Processes, and Innovating Chemical Technologies** 



- Property-based design: How best to leverage physicochemical properties in compound design
- Streamlining the hit-to-candidate process: Strategies to most effectively advance chemical matter from hit to clinical candidate
- Emerging chemical technologies in drug discovery
- Design of BRo5 drugs: Lessons learned from the degrader, molecular glue, and natural product chemical space



Arun Thottumkara Director Chemistry **Odyssey Therapeutics** 

#### **ABOUT THE SPEAKER**

Arun Thottumkara, PhD is a Director of Chemistry at Odyssey Therapeutics, a biotechnology company focused on discovering and developing novel medicines for immunology and oncology. At Odyssey, he leads multi-disciplinary drug discovery teams. Prior to Odyssey Therapeutics, Arun spent several years at Denali Therapeutics, where his focus was on small molecule discovery for neurodegenerative diseases. He began his drug discovery career as one of the first employees at Revolution Medicines, a biotech company focused on RAS-addicted cancers. Over the course of his career, Arun and his teams have advanced multiple molecules into clinical development for neurodegeneration and oncology.

10:00 - 11:05 PT

**BOOK NOW!** 

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 

11:10 - 12:10 PT

**SOLUTION FOCUS ROUNDTABLE 2** 

The Best Methods for Synthesizing Quantities **Ranging From Milligrams To Kilograms** 



Speaker TBC

ABOUT THE SPEAKER Speaker TBC

L 12:15 - 13:15 PT

**ROUNDTABLE 3** 

Streamlining the hit-to-candidate process: Strategies to most effectively advance chemical matter from hit to clinical candidate

Speaker TBC

ABOUT THE SPEAKER Speaker TBC

13:15 - 14:40 PT

**NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS** 

14:40 - 15:10 PT

AFTERNOON KEYNOTE PRESENTATION See Page 6

L 15:10 - 16:10 PT

**ROUNDTABLE 4** 

**Pioneering Perspectives and Forward-thinking** Approaches in Design and Synthesis for Drug Discovery



Yoshi Satoh Vice President of Chemistry **Rev Therapeutics** 

**ABOUT THE SPEAKER** Speaker TBC

L 16:10 - 16:30 PT

AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT

**PANEL DISCUSSION** 

17:00 - 18:00 PT

**DRINKS & CANAPES RECEPTION** 











# **Event Day**

## **Integrated Drug Discovery**

Overcoming the high attrition rates of the development process, particularly in drug discovery and optimization remains a significant hurdle and a top priority in the pharma and biotech sector. Here we will explore effective strategies to break down discipline segmentation and foster an improved integrated approach to drug discovery.

STRATEGY MEETING WEST COAST USA 2024 🚃 Wednesday, 22nd May 2024 🕺 Hard Rock Hotel San Diego

08:00 - 08:30 PT

BREAKFAST & REGISTRATION



**OPENING KEYNOTE PRESENTATION** 



O9:00 - 10:00 PT

**ROUNDTABLE 1** 

Leveraging ADME-PKPD relationships and mechanistic toxicology while building bridges between translational sciences is crucial for effective drug development, spanning from molecules to medicines





Sanjeev Thohan Scientific Advisory Board Member Cogentis Therapeutics/Phoenix Molecular Designs

#### ABOUT THE SPEAKER


Sanieev is currently the President of SARx Consulting after 25 years in industry his practice encompasses Fractional Leadership of R&D activities from Lead Optimization to IND filing and clinical trial design. He is also a SME for clinical biomarker prosecution, and translational mechanistic studies as they relate to clinical trials. He personally generated and overseen programs for both small molecules and antibody drug conjugates (ADC) in the Anti-viral, Anti-infective, Anti-inflammatory, Biodefense, Cardiovascular/ Metabolic and Oncology, therapeutic areas. He is an active mentor and fundraiser for startups as well as a Scientific Advisory Board member and founder of several innovative companies.



**10:00 - 11:05 PT** 

**REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS** 

Fresh Life Science Insights



**BOOK NOW!** 







11:10 - 12:10 PT

**SOLUTION FOCUS ROUNDTABLE 2** 

Addressing the Design Approaches that Target the Undruggable Proteins from Drug Discovery to **Clinical Trials** 



Speaker TBC

ABOUT THE SPEAKER

Speaker TBC



L 12:15 - 13:15 PT

**ROUNDTABLE 3** 

**Ideas About Automating Decision Making Steps To Accelerate Integrated Discovery** 



Yoshi Satoh Vice President of Chemistry **Rev Therapeutics** 

ABOUT THE SPEAKER Speaker TBC

13:15 - 14:40 PT

**NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS** 

14:40 - 15:10 PT

AFTERNOON KEYNOTE PRESENTATION

15:10 - 16:10 PT

**ROUNDTABLE 4** 

**Exploring Translational Challenges and Triumphs in** Integrated Drug Discovery for Real-World Clinical **Impact** 





**ABOUT THE SPEAKER** Speaker TBC

16:10 - 16:30 PT

AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT

PANEL DISCUSSION

See Page 6

17:00 - 18:00 EST

**DRINKS & CANAPES RECEPTION** 





conducive for conversations at any stage, whether it was around the roundtables, whether it was during the talks, the panels or whether in the one-on-one meetings. The 1:1 meetings were perfectly scheduled. A differentiator for Proventa is that most of the people that come here really have a need and they're looking for that need to be met, and so the conversations are really targeted and focused towards those needs and how we can meet those needs."

BIORASI


Associate Director













# Find your new partner, explore our digital storefronts

www.pharmafeatures.com

Contact us to discuss how we can help generate growth for your business

#### **Dex Marco Guibelondo**

Marketing Content Writer, Proventa International Editor-in-Chief, PharmaFEATURES

dex@proventainternational.com



**OUR FACE** TO FACE MEETING **IN MAY** 2024



Hyatt Regency Princeton

STRATEGY

Hard Rock Hotel San Diego

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS STRATEGY MEETING EAST COAST USA 2024

DRUG DISCOVERY BIOLOGY

STRATEGY MEETING WEST COAST USA 2024

& BIOINFORMATICS

MEDICINAL

CHEMISTRY

MEDICINAL CHEMISTRY

**CLINICAL OPERATIONS &** CLINICAL TRIAL SUPPLY CHAIN STRATEGY MEETING EAST COAST USA 2024

CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN

### **Hotel & Venue**



**SAN DIEGO** 

#### **Hard Rock Hotel San Diego**

downtown San Diego. Tour the Gaslamp Quarter on an Electra bike and walk a block to Petco Park.

#### **BOOK NOW!**

We only have limited rooms available!

Hotel Details >

Map & Directions >









Visit us on our website to know more about our meetings

www.proventainternational.com